The Johnson & Johnson vaccine in Italy is recommended for people over 60. “The Janssen vaccine, which is approved for use from 18 years of age, should preferentially be administered to people over the age of 60, that is, to those who, having a high risk of serious and lethal disease, they need to be protected as a priority “, reads a note signed by Franco Locatelli, president of the Superior Health Council, Nicola Magrini, general manager of Aifa, and Gianni Rezza, director General of the Prevention of the Ministry of Health. The decision came after the “pronouncement of Ema”, the European drug agency, and after the “opinion of the CTS of Aifa, which reiterates the extreme rarity of thrombosis events associated with thrombocytopenia described following vaccination against Covid -19 carried out with the Janssen – Johnson & Johnson vaccine “. “Considering that this vaccine has proven to be certainly effective in reducing the risk of serious illness, hospitalization and death related to COVID-19, the same conditions of use as the Vaxzevria vaccine are recommended,” namely the AstraZeneca vaccine.
MAGRINI: “IN ITALY J&J FOR THE ELDERLY GROUP”
“As expected, the EMA and the FDA have had extensive exchanges of information on Johnson & Johnson and have concluded that the rare cases of thrombosis are at the limit of evaluability, if not negligible. So the vaccine is for everyone and the Italy places him in the elderly bracket where certainly the benefits are greater than the risks “, said the director of the Italian Medicines Agency (Aifa) Nicola Magrini, guest of Otto e mezzo on La7.
“Vaccine administrations are growing, our vaccination capacity allows us to reach 500 thousand doses per day – he added – it is a capacity that we already have but it depends on the delivery of vaccines, which is a factor not really in our hands”, he added.